Vyome Holdings Inc (HIND)
Vyome Holdings Inc. is a NASDAQ-listed common stock company focused on clinical-stage specialty pharmaceuticals. Based in Cambridge, Massachusetts, the company develops therapeutic candidates for immuno-inflammatory and rare diseases in the United States through its pharmaceutical and biotechnology operations. Its pipeline includes VT-1953, a topical gel in phase 2 development for bacterial conjunctivitis, and VB-1953, which is being studied in phase 2 for inflammatory acne. Vyome also develops VT-1908, a topical eye drop candidate intended for immunoinflammatory eye conditions. In addition, the company is advancing antifungal products through its molecular replacement therapy platform and has a collaboration and license agreement with Sun Pharma Laboratories Limited for next-generation antifungal product development and commercialization.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HIND
|
$1.95
|
-10.0% Downside
|
Fair
|
$11.50
|
430.0% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-1.4x
|
2.3x
|
99.7x
|
15.371 M
|
7.754 M
|
0.1%
|
46.4%
|
-8.6
|
—
|
45.6%
|
